This page shows the latest Sumitomo Dainippon news and features for those working in and with pharma, biotech and healthcare.
Aside from its collaboration with BMS, Exscientia has a number of additional collaborations in place with other pharma companies, including Bayer, Sanofi and Dainippon Sumitomo.
The positive trial result is also good news for Japanese drugmaker Sumitomo Dainippon, which agreed a $3bn upfront deal to acquire a 45% stake in Myovant – and control of four other
Could acquire up to 11 Roivant spinouts. Japanese pharma company Sumitomo Dainippon has announced a strategic deal with Roivant Sciences, a biotech holding company headed by entrepreneur Vivek Ramaswamy, for a ... Sumitomo Dainippon's expertise in
drug. The French company signed an agreement with Sumitomo Dainippon Pharma in 2017 for development rights to the drug in Asian markets including Japan, which has a slightly lower bar for
The drug is already in phase III testing in Japan via a partnership with Sumitomo Dainippon Pharma, and Roivant will now take the lead on phase III trials in the US, ... Europe and other territories not covered by the Sumitomo alliance.
Prior to that he held a number of senior commercial with Sepracor, prior to its acquisition by Dainippon Sumitomo Pharma (DSP) and Solvay Pharmaceuticals, which is now part of AbbVie.
More from news
Approximately 1 fully matching, plus 15 partially matching documents found.
We have so far discovered four preclinical drug candidates, and recently announced the first drug designed by AI in partnership with Sumitomo Dainippon Pharma to enter human trials.
2020.”. Central Nervous System. 2017 was a quiet year in CNS. The most prominent growing companies were Merck &Co (49.8%), Takeda (39.1%) and Sumitomo Dainippon Pharma (25%), with growth ... However, the imminent US patent expiry of Sumitomo
790. Tolero Pharma (US). Dainippon Sumitomo (Japan). Acquisition with milestones. Portfolio, including alvocidib, a CDK9 inhibitor with phase II completed in AML. ... Tolero Pharmaceuticals. Dainippon Sumitomo. $780m. Upfront payment of $200m.
If apomorphine is the only product, the acquisition of the company by Sunovion (the US subsidiary of Dainippon Sumitomo) for $645m, paying a hefty 123% share price premium, looks very expensive ... 645. Cynapsys (CA). Sunovion (US) (Dainippon Sumitomo).
Edison Pharmaceuticals/ Dainippon Sumitomo Pharma. Strategic alliance. Extends development/ commercialisation agreement to EPI 743 and EPI 589 for mitochondrial disease, includes stock purchase and 10 further NCEs.
More from intelligence
Approximately 0 fully matching, plus 8 partially matching documents found.
Sunovion was created after the acquisition of Iwicki's former company Sepracor by Dainippon Sumitomo Pharmaceuticals.
Andrews joins Boston Biomedical – a subsidiary of Japanese firm Dainippon Sumitomo Pharma – to bulk up its commercialisation efforts as lead drug candidate BBI608 nears phase III completion for use in metastatic
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Beautiful things happen when you put the right ingredients together. It’s the reason that we mix behaviour change experts with...